vs
Atara Biotherapeutics, Inc.（ATRA）与REZOLVE AI PLC（RZLV）财务数据对比。点击上方公司名可切换其他公司
Atara Biotherapeutics, Inc.的季度营收约是REZOLVE AI PLC的1.3倍（$1.6M vs $1.2M）
Atara Biotherapeutics是一家临床阶段生物技术企业，专注研发同种异体T细胞免疫疗法，适应症覆盖肿瘤、自身免疫疾病及感染性疾病，业务主要布局北美、欧洲及亚太市场，致力于为有未满足医疗需求的患者提供新型治疗方案。
REZOLVE AI PLC是总部位于英国的科技企业，开发人工智能驱动的移动互动与即时交易平台，支持用户直接从音频、视频、印刷内容中完成购买，服务欧洲、北美及部分亚太市场的零售、消费品与媒体客户。
ATRA vs RZLV — 直观对比
营收规模更大
ATRA
是对方的1.3倍
$1.2M
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.6M | $1.2M |
| 净利润 | — | $-13.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -808.4% |
| 净利率 | — | -1078.8% |
| 营收同比 | -95.1% | — |
| 净利润同比 | 73.2% | — |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRARZLV
| Q4 25 | $1.6M | — | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $17.6M | $1.2M | ||
| Q1 25 | $98.1M | — | ||
| Q4 24 | $32.8M | — | ||
| Q3 24 | $40.2M | — | ||
| Q2 24 | $28.6M | — | ||
| Q1 24 | $27.4M | — |
净利润ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | $-4.3M | — | ||
| Q2 25 | $2.4M | $-13.0M | ||
| Q1 25 | $38.0M | — | ||
| Q4 24 | $-12.7M | — | ||
| Q3 24 | $-21.9M | — | ||
| Q2 24 | $-19.0M | — | ||
| Q1 24 | $-31.8M | — |
营业利润率ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | -103.5% | — | ||
| Q2 25 | 18.2% | -808.4% | ||
| Q1 25 | 39.5% | — | ||
| Q4 24 | -37.3% | — | ||
| Q3 24 | -54.1% | — | ||
| Q2 24 | -63.7% | — | ||
| Q1 24 | -114.2% | — |
净利率ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | -124.6% | — | ||
| Q2 25 | 13.6% | -1078.8% | ||
| Q1 25 | 38.7% | — | ||
| Q4 24 | -38.8% | — | ||
| Q3 24 | -54.5% | — | ||
| Q2 24 | -66.5% | — | ||
| Q1 24 | -116.1% | — |
每股收益（稀释后）ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | $-0.32 | — | ||
| Q2 25 | $0.19 | — | ||
| Q1 25 | $3.50 | — | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $-2.93 | — | ||
| Q2 24 | $-3.10 | — | ||
| Q1 24 | $-5.65 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-38.5M | $-14.3M |
| 总资产 | $20.2M | $80.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRARZLV
| Q4 25 | $8.5M | — | ||
| Q3 25 | $13.7M | — | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $13.8M | — | ||
| Q4 24 | $42.5M | — | ||
| Q3 24 | $67.2M | — | ||
| Q2 24 | $35.3M | — | ||
| Q1 24 | $46.2M | — |
股东权益ATRARZLV
| Q4 25 | $-38.5M | — | ||
| Q3 25 | $-36.6M | — | ||
| Q2 25 | $-35.0M | $-14.3M | ||
| Q1 25 | $-55.1M | — | ||
| Q4 24 | $-97.3M | — | ||
| Q3 24 | $-90.5M | — | ||
| Q2 24 | $-110.9M | — | ||
| Q1 24 | $-98.3M | — |
总资产ATRARZLV
| Q4 25 | $20.2M | — | ||
| Q3 25 | $30.2M | — | ||
| Q2 25 | $36.9M | $80.1M | ||
| Q1 25 | $62.0M | — | ||
| Q4 24 | $109.1M | — | ||
| Q3 24 | $142.7M | — | ||
| Q2 24 | $117.3M | — | ||
| Q1 24 | $165.3M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-50.9M | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ATRARZLV
| Q4 25 | $-50.9M | — | ||
| Q3 25 | $-9.8M | — | ||
| Q2 25 | $-7.3M | $-4.9M | ||
| Q1 25 | $-28.1M | — | ||
| Q4 24 | $-24.5M | — | ||
| Q3 24 | $-4.0M | — | ||
| Q2 24 | $-10.6M | — | ||
| Q1 24 | $-29.6M | — |
自由现金流ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-24.6M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-10.7M | — | ||
| Q1 24 | $-29.7M | — |
自由现金流率ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -75.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -37.3% | — | ||
| Q1 24 | -108.7% | — |
资本支出强度ATRARZLV
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.5% | — |
现金转化率ATRARZLV
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | -0.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
